Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.
CSF
KFLC
Multiple sclerosis
OCB
biomarkers
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
9
5
2019
medline:
29
7
2021
entrez:
9
5
2019
Statut:
ppublish
Résumé
To validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). We performed a multicenter study including 745 patients from 18 centers (219 controls and 526 clinically isolated syndrome (CIS)/MS patients) with a known oligoclonal IgG band (OCB) status. KFLC and LFLC were measured in paired cerebrospinal fluid (CSF) and serum samples. Gaussian mixture modeling was used to define a cut-off for KFLC and LFLC indexes. The cut-off for the KFLC index was 6.6 (95% confidence interval (CI) = 5.2-138.1). The cut-off for the LFLC index was 6.9 (95% CI = 4.5-22.2). For CIS/MS patients, sensitivity of the KFLC index (0.88; 95% CI = 0.85-0.90) was higher than OCB (0.82; 95%CI = 0.79-0.85; Compared with OCB, the KFLC index is more sensitive but less specific for diagnosing CIS/MS. Lacking an elevated KFLC index is more powerful for excluding MS compared with OCB but the latter is more important for ruling in a diagnosis of CIS/MS.
Identifiants
pubmed: 31066634
doi: 10.1177/1352458519845844
pmc: PMC7350201
doi:
Substances chimiques
Biomarkers
0
Immunoglobulin kappa-Chains
0
Immunoglobulin lambda-Chains
0
Oligoclonal Bands
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-923Références
J Neuroimmunol. 2013 Sep 15;262(1-2):1-10
pubmed: 23890808
Brain. 2002 Jul;125(Pt 7):1462-73
pubmed: 12076997
Arch Neurol. 2005 Apr;62(4):574-7
pubmed: 15824255
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 2014 Sep 23;83(13):1210-6
pubmed: 25150289
Clin Neurol Neurosurg. 2018 Nov;174:220-229
pubmed: 30278299
PLoS One. 2014 Feb 25;9(2):e89945
pubmed: 24651567
J Neuroimmunol. 2010 Dec 15;229(1-2):263-71
pubmed: 20870296
Neurology. 1985 Oct;35(10):1443-9
pubmed: 3929159
J Immunol Methods. 2013 Apr 30;390(1-2):74-80
pubmed: 23376556
J Immunol Methods. 2011 Aug 31;371(1-2):170-3
pubmed: 21704629
Ann Neurol. 1986 Jul;20(1):63-9
pubmed: 3090930
Clin Chem Lab Med. 2018 Mar 28;56(4):609-613
pubmed: 29087953
Eur J Pharmacol. 2006 Mar 8;533(1-3):319-26
pubmed: 16455071
Clin Chem. 2001 Apr;47(4):673-80
pubmed: 11274017
Mult Scler. 2017 Oct;23(11):1496-1505
pubmed: 27899552
Neurology. 2008 Mar 25;70(13 Pt 2):1079-83
pubmed: 17881717
Scand J Clin Lab Invest. 1975 Sep;35(5):407-12
pubmed: 810881
Brain. 2018 Apr 1;141(4):1075-1084
pubmed: 29462277
PLoS One. 2014 Apr 02;9(4):e88680
pubmed: 24695382
J Clin Immunol. 2005 Jul;25(4):338-45
pubmed: 16133990
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Eur J Neurol. 2018 Sep;25(9):1134-1139
pubmed: 29683546
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler Int. 2016;2016:2303857
pubmed: 28116160
Mult Scler. 2015 Jul;21(8):1013-24
pubmed: 25680984
J Neuroimmunol. 2017 Aug 15;309:31-33
pubmed: 28601282
J Neurol. 2008 Oct;255(10):1508-14
pubmed: 18685917
J Neuroimmunol. 2013 Oct 15;263(1-2):116-20
pubmed: 23916392
J Neurol. 1987 Jun;234(5):303-7
pubmed: 3112315
Mult Scler. 2016 Apr;22(4):502-10
pubmed: 26199348
Neurology. 1987 Aug;37(8):1334-8
pubmed: 3112610
PLoS One. 2015 Nov 25;10(11):e0143375
pubmed: 26606531
Mult Scler. 2013 Nov;19(13):1802-9
pubmed: 23695446